Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis (Q34610283)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

author name string

Katherine F Croom

1

1 reference

Europe PubMed Central

3 August 2017

M Asif A Siddiqui

2

1 reference

Europe PubMed Central

3 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 2009

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

69

1 reference

Europe PubMed Central

3 August 2017

11

1 reference

Europe PubMed Central

3 August 2017

1513-1532

1 reference

Europe PubMed Central

3 August 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200969110-00008

0 references

Characterization of etoricoxib, a novel, selective COX-2 inhibitor

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969110-00008

21 January 2018

The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969110-00008

21 January 2018

Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The burden of musculoskeletal disease--a global perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The burden of ankylosing spondylitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New horizons and perspectives in the treatment of osteoarthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of etoricoxib on the pharmacokinetics of phenytoin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibitors of cyclooxygenases: mechanisms, selectivity and uses

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Celecoxib inhibits 5-lipoxygenase

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of etoricoxib in patients with renal impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coxibs and heart disease: what we have learned and what else we need to know

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/19634927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200969110-00008

1 reference

Europe PubMed Central

3 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34610283&oldid=1755853410"